Lightbridge Corporation — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. Lightbridge is developing and seeking to commercialize next-generation metallic nuclear fuel. It reported no revenue in either Q1 2021 or Q1 2020.
Financial results and position
| Metric | Q1 2021 / March 31, 2021 | Prior comparable period / December 31, 2020 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.15 million | $2.33 million in Q1 2020 |
| Operating loss | $2.05 million | $2.33 million in Q1 2020 |
| Net loss | $2.01 million | $2.26 million in Q1 2020 |
| Net loss attributable to common shareholders / diluted loss per share | $2.20 million / $0.33 | $2.44 million / $0.74 in Q1 2020 |
| Cash and cash equivalents | $15.24 million | $21.53 million |
| Operating cash flow | $(6.30) million | $(2.02) million in Q1 2020 |
| Current liabilities | $0.63 million | $4.58 million |
| Total liabilities / debt | $0.63 million / no debt or credit lines | — |
| Stockholders’ equity | $15.33 million | $17.21 million |
Gross margin is not applicable because the company had no revenue. The company received $103,000 in DOE grant income, presented as other operating income, with corresponding research and development costs. It also recorded a $34,000 foreign transaction gain related to its Framatome settlement.
Changes, cash use and capital
- Operating expenses decreased 7% year over year: general and administrative expense fell 8% to $1.78 million, and R&D expense fell 5% to $369,000. Management cited lower professional fees and employee costs, partly offset by outside R&D and patent expenses.
- Net loss narrowed 11% to $2.01 million. Loss per common share improved to $0.33 from $0.74, while weighted-average shares increased to 6.59 million from 3.29 million.
- Operating cash use increased to $6.30 million, including payment of the $4.2 million Framatome invoices previously accrued as a liability. Cash declined $6.30 million during the quarter; there were no investing or financing cash flows in Q1 2021.
- At March 31, common shares outstanding were 6.59 million. Preferred shares, options, warrants, RSUs and accrued preferred dividends represented additional potential dilution. Preferred stock carries 7% annual dividends paid in kind.
- The company had no ATM sales in Q1 2021. A $75 million Form S-3 became effective April 5, 2021; due to public-float offering limits, the company said it could offer up to $9 million of common stock under its amended ATM arrangement.
Outlook, developments and risks
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern for the 12 months following the filing. Cash was described as sufficient for budgeted expenditures through Q1 2022, but management cited uncertain R&D needs and projected negative cash flows. It estimated $9–10 million of expenditures over the next 12–15 months and ongoing negative operating cash flow averaging about $0.8 million per month.
- Future funding depends on equity or convertible financing, strategic relationships and government support. Shareholder approval to increase authorized common shares was being sought in 2021. Financing may be unavailable or dilutive; delaying R&D could preserve cash but extend development.
- Management said the fuel-development timeline could be 15–20 years before first batch-reload orders in large commercial reactors if additional ATR test loops are not funded and installed. The company says it cannot fund those loops itself; without them, additional testing may be needed. It expects the first SMRs that could use its fuel to begin operating in 2029.
- DOE GAIN awards support work with Idaho National Laboratory (INL) and Pacific Northwest National Laboratory (PNNL). The INL project was extended through September 30, 2021; the PNNL project, valued at about $664,000 with three-quarters funded by DOE, was expected to start in the first half of 2021.
- Management reported a successful surrogate-material demonstration of its six-foot fuel-rod manufacturing process on May 11, 2021, and two new patents in 2021. These are development milestones, not commercial sales or proof of commercial readiness.
- COVID-19, laboratory staffing and export-control matters may delay R&D. Other key risks include technology testing and regulatory approval, access to test reactors, dependence on partners and government funding, competition, commercialization costs, and the long development timeline.
- The Framatome settlement resolved arbitration and related proceedings; the inactive Enfission joint venture was dissolved March 23, 2021, after Lightbridge paid approximately $4.2 million. A former CFO’s OSHA appeal remained pending; management said it would defend the matter and did not expect findings against the company.
- Disclosure controls were assessed as effective at quarter-end. Management said the material weakness previously disclosed in the 2020 Form 10-K had been remediated.
Key facts for investors to verify
- Whether Lightbridge obtains shareholder approval and raises sufficient capital, and the resulting dilution and financing terms.
- Actual cash burn and R&D commitments versus management’s $9–10 million expenditure estimate, particularly given the settlement-related cash outflow in Q1.
- Funding and availability of ATR test loops, progress and timing of INL/PNNL work, and any resulting changes to the 15–20-year development timeline.
- Whether DOE and other support covers a meaningful share of future development costs and whether the surrogate manufacturing results translate to uranium fuel fabrication and testing.
- Potential dilution from preferred dividends, convertible securities, options, warrants, RSUs and any future ATM or other equity issuance.